WO2008024299A3 - Combination with bis(thiohydrazide amides) for treating cancer - Google Patents

Combination with bis(thiohydrazide amides) for treating cancer Download PDF

Info

Publication number
WO2008024299A3
WO2008024299A3 PCT/US2007/018354 US2007018354W WO2008024299A3 WO 2008024299 A3 WO2008024299 A3 WO 2008024299A3 US 2007018354 W US2007018354 W US 2007018354W WO 2008024299 A3 WO2008024299 A3 WO 2008024299A3
Authority
WO
WIPO (PCT)
Prior art keywords
bis
combination
treating cancer
thiohydrazide amides
amides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/018354
Other languages
French (fr)
Other versions
WO2008024299A2 (en
Inventor
Eric Jacobson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Priority to EP07811430A priority Critical patent/EP2059236A2/en
Priority to US12/310,273 priority patent/US20100068174A1/en
Priority to AU2007288334A priority patent/AU2007288334A1/en
Priority to JP2009525581A priority patent/JP2010501558A/en
Publication of WO2008024299A2 publication Critical patent/WO2008024299A2/en
Publication of WO2008024299A3 publication Critical patent/WO2008024299A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed herein are methods of treating an immunosensitive cancer with bis(thio-hydrazide amides) or pharmaceutically -acceptable salts thereof and an immunotherapy.
PCT/US2007/018354 2006-08-21 2007-08-20 Combination with bis(thiohydrazide amides) for treating cancer Ceased WO2008024299A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP07811430A EP2059236A2 (en) 2006-08-21 2007-08-20 Combination with bis(thiohydrazide amides) for treating cancer
US12/310,273 US20100068174A1 (en) 2006-08-21 2007-08-20 Combination with bis (thiohydrazide amides) for treating cancer
AU2007288334A AU2007288334A1 (en) 2006-08-21 2007-08-20 Combination with bis(thiohydrazide amides) for treating cancer
JP2009525581A JP2010501558A (en) 2006-08-21 2007-08-20 Combination with bis (thiohydrazide amide) to treat cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83911306P 2006-08-21 2006-08-21
US60/839,113 2006-08-21

Publications (2)

Publication Number Publication Date
WO2008024299A2 WO2008024299A2 (en) 2008-02-28
WO2008024299A3 true WO2008024299A3 (en) 2008-04-17

Family

ID=38947347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018354 Ceased WO2008024299A2 (en) 2006-08-21 2007-08-20 Combination with bis(thiohydrazide amides) for treating cancer

Country Status (5)

Country Link
US (1) US20100068174A1 (en)
EP (1) EP2059236A2 (en)
JP (1) JP2010501558A (en)
AU (1) AU2007288334A1 (en)
WO (1) WO2008024299A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI330079B (en) 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
DK1781604T3 (en) 2004-06-23 2013-09-16 Synta Pharmaceuticals Corp BIS (THIO-HYDRAZIDE-AMID) SALTS FOR TREATMENT OF CANCERS
AU2006236378B2 (en) 2005-04-15 2010-12-02 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
AU2006279891B2 (en) 2005-08-16 2010-03-11 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation
MX2009001877A (en) 2006-08-21 2009-03-02 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders.
EP2076254A2 (en) * 2006-08-31 2009-07-08 Synta Pharmaceuticals Corporation Combination with bis(thiohydrazide amides) for treating cancer
US7645904B2 (en) 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
US8618170B2 (en) 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
WO2009105257A1 (en) 2008-02-21 2009-08-27 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)
US8461199B2 (en) 2008-10-22 2013-06-11 Synta Pharmaceuticals Corp. Transition metal complexes of a bis[thio-hydrazide amide] compound
CA2741189A1 (en) 2008-10-22 2010-04-29 Synta Pharmaceuticals Corp. Transition metal complexes of bis[thiohydrazide amide] compounds
US8525776B2 (en) * 2008-10-27 2013-09-03 Lenovo (Singapore) Pte. Ltd Techniques for controlling operation of a device with a virtual touchscreen
AU2009322603B2 (en) 2008-12-01 2013-08-29 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2011069159A2 (en) * 2009-12-04 2011-06-09 Synta Pharmaceuticals Corp. Bis[thiohydrazide amide] compounds for treating leukemia
WO2011133673A1 (en) 2010-04-20 2011-10-27 Synta Pharmaceuticals Corp. Use of bis [thiohydrazide amide] compounds such as elesclomol for treating cancers
KR101652606B1 (en) * 2011-06-06 2016-08-30 아케비아 테라퓨틱스 인코포레이티드 Compounds and compositions for stabilizing hypoxia inducible factor-2 alpha as a method for treating cancer
US20130149392A1 (en) * 2011-12-12 2013-06-13 Synta Pharmaceuticals Corp. Method of treating non-small cell lung cancer with bis-(thiohydrazide)amide compounds
EP2983791A4 (en) 2013-04-11 2016-11-09 Brigham & Womens Hospital METHODS AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
KR20180064540A (en) * 2015-10-23 2018-06-14 다이이찌 산쿄 가부시키가이샤 MDM2 Inhibitor Therapy for Cancer Treatment
US20230390424A1 (en) * 2020-09-11 2023-12-07 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064826A1 (en) * 2003-01-15 2004-08-05 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
WO2006009940A1 (en) * 2004-06-23 2006-01-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
WO2006033913A2 (en) * 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
WO2006062732A2 (en) * 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
WO2007021881A1 (en) * 2005-08-16 2007-02-22 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI297335B (en) * 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
US6924312B2 (en) * 2001-07-10 2005-08-02 Synta Pharmaceuticals Corp. Taxol enhancer compounds
ITPD20010240A1 (en) * 2001-10-10 2003-04-10 Sit La Precisa Spa VALVE GROUP FOR THE CONTROL OF THE DELIVERY OF A COMBUSTIBLE GAS.
AU2005306471B2 (en) * 2004-11-19 2009-12-17 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amides) for increasing Hsp70 expression
AU2006236378B2 (en) * 2005-04-15 2010-12-02 Synta Pharmaceuticals Corp. Combination cancer therapy with bis(thiohydrazide) amide compounds
CA2603314A1 (en) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Methods of increasing natural killer cell activity for therapy
RU2407734C2 (en) * 2005-05-16 2010-12-27 Синта Фармасьютиклз Корп. Bis(thiohydrazide amide)disalt synthesis method (versions)
AU2007288336B2 (en) * 2006-08-21 2011-04-21 Synta Pharmaceuticals Corp. Bis(thiohydrazide amides) for use in preventing or delaying the recurrence of melanoma
WO2008024305A2 (en) * 2006-08-21 2008-02-28 Synta Pharmaceuticals Corp. Bis (thiohydrazide amides) for treating melanoma
MX2009001877A (en) * 2006-08-21 2009-03-02 Synta Pharmaceuticals Corp Compounds for treating proliferative disorders.
AU2007288339B2 (en) * 2006-08-21 2011-08-18 Synta Pharmaceuticals Corp. Compounds for treatment of proliferative disorders
TW200826926A (en) * 2006-09-11 2008-07-01 Synta Pharmaceuticals Corp Bis (thiohydrazide amides) formulation
US7645904B2 (en) * 2006-09-15 2010-01-12 Synta Pharmaceuticals Corp. Purification of bis(thiohydrazide amides)
WO2008082579A1 (en) * 2007-01-03 2008-07-10 Synta Pharmaceuticals Corp. Method for treating cancer
WO2008136976A2 (en) * 2007-04-30 2008-11-13 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
US8618170B2 (en) * 2007-11-09 2013-12-31 Synta Pharmaceuticals Corp. Oral formulations of bis(thiohydrazide amides)
WO2009123704A2 (en) * 2008-03-31 2009-10-08 Synta Pharmaceuticals Corp. Process for preparing bis(thiohydrazide amides)

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064826A1 (en) * 2003-01-15 2004-08-05 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amide) compounds for treating multi-drug resistant cancer
WO2006009940A1 (en) * 2004-06-23 2006-01-26 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) salts for treatment of cancers
WO2006033913A2 (en) * 2004-09-16 2006-03-30 Synta Pharmaceuticals Corp. Bis (thio-hydrazide amides) for treament of hyperplasia
WO2006062732A2 (en) * 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
WO2007021881A1 (en) * 2005-08-16 2007-02-22 Synta Pharmaceuticals Corp. Bis(thio-hydrazide amide) formulation

Also Published As

Publication number Publication date
US20100068174A1 (en) 2010-03-18
AU2007288334A1 (en) 2008-02-28
WO2008024299A2 (en) 2008-02-28
EP2059236A2 (en) 2009-05-20
JP2010501558A (en) 2010-01-21

Similar Documents

Publication Publication Date Title
WO2008024299A3 (en) Combination with bis(thiohydrazide amides) for treating cancer
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
CY1121135T1 (en) SUBSTITUTED FOUR-CYCLINES COMPOUNDS FOR THE TREATMENT OF INFLAMMATIVE SKIN DISORDERS
CY1114926T1 (en) ANTIBODIES AND IMMUNITIES AND USES OF THESE
BR112013002012A2 (en) Methods and Compositions for Liver Cancer Therapy
MX2009003938A (en) Antibodies and immunoconjugates and uses therefor.
MX2009009292A (en) Ppar active compounds.
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
BRPI0819819A2 (en) Preparations, methods and useful kits for cough treatment
IL192568A0 (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP2152142A4 (en) Device and assembly for positioning, stabilizing and treating an eye
BRPI0921321A2 (en) methods for the treatment of tumors and tumors
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
MX2011010955A (en) Adjuvant cancer therapy.
DK2340042T3 (en) Methods and Preparations for the Treatment of Cancer
NZ579478A (en) Epha3 antibodies for the treatment of solid tumors
MX2009013982A (en) Compositions comprising tryptophan hydroxylase inhibitors.
MX2009004030A (en) Antimicrobial articles and method of manufacture.
EP2144887A4 (en) Dosages and methods for the treatment of cancer
WO2008036415A3 (en) Compact e-beam source for generating x-rays
WO2007081878A8 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
GB0604471D0 (en) Device and method for the treatment of tumours
EP1996211A4 (en) Gallium compositions for the treatment of liver cancer and methods of use
WO2010148177A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811430

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009525581

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007288334

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007811430

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: 2007288334

Country of ref document: AU

Date of ref document: 20070820

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12310273

Country of ref document: US